Multiple Myeloma | Disease Landscape & Forecast | G7 | 2023
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved novel therapies such as CAR T-cell therapies (Bristol Myers Squibb / Bluebird Bio’s Abecma and Janssen’s Carvykti) and bispecific antibodies (Janssen’s Tecvayli and Talvey, and Pfizer’s Elrexfio) have expanded the number of options available. Emerging therapies—Venclexta / Venclyxto and next-generation IMiDs iberdomide and mezigdomide—will compete fiercely. Nevertheless, clinical and commercial potential remains for therapies with improved efficacy and therapies able to treat underserved patient populations, such as those with smoldering multiple myeloma.
Questions answered
- What is the size of the drug-treatable multiple myeloma population, and how do drug-treatment rates vary by geography, line of therapy, and over time?
- How will the use of Revlimid and Velcade change over the forecast period, and what impact will generic entry have on the market?
- How will physicians manage the treatment sequencing of BCMA-targeted therapies such as CAR T cells, antibody-drug conjugates, and bispecific antibodies?
- What are thought leaders’ opinions of therapies in late-stage development, such as the bispecific antibody cevostamab, the apoptosis-inducing agent Venclexta / Venclyxto, and the CELMoDs iberdomide and mezigdomide?
- What are the drivers of, and constraints on, the therapy market?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: 18 country-specific interviews with thought-leading hematologist-oncologists supported by survey data collected for this and other Clarivate research
Epidemiology: Incidence of multiple myeloma by country, segmented by line of therapy and symptomatic status
Emerging therapies: Phase 3: 5 drugs; coverage of select Phase 1 and 2 products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
